# EDGAR Filing Document

**Accession Number:** 0001683553
**File Stem:** 0001193125-26-239230
**Filing Date:** 2026-5
**Character Count:** 8147
**Document Hash:** 05797e7e838db91dd4319ed4b60f522f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-239230.hdr.sgml**: 20260526

**ACCESSION NUMBER**: 0001193125-26-239230

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 9

**CONFORMED PERIOD OF REPORT**: 20260521

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260526

**DATE AS OF CHANGE**: 20260526

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SPRUCE BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001683553
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 812154263
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39594
- **FILM NUMBER:** 261019629

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BOULEVARD, SUITE 740
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** (415) 655-4168

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BOULEVARD, SUITE 740
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** May 21, 2026<br>

------

Spruce Biosciences, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39594 | 81-2154263 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 611 Gateway Boulevard**,** Suite 740 |  |  |
| South San Francisco**,** California |  | 94080 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 415**-**343-5986<br>

**Not Applicable**<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | SPRB | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

Spruce Biosciences, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") on May 21, 2026, in a virtual format. As of March 24, 2026, the record date for the Annual Meeting, there were 1,372,278 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting, of which 903,893 shares, representing approximately 65.86% of the outstanding shares, were present virtually or represented by proxy, constituting a quorum. The final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting are set forth below. **Proposal 1: Election of Class III Directors.**

The Company's stockholders elected each of the three nominees named below to serve as Class III directors of the Company until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Nominee** | &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Withheld** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;Michael Grey | &nbsp;&nbsp;276159 | &nbsp;&nbsp;23715 | &nbsp;&nbsp;604019 |
| &nbsp;&nbsp;Camilla V. Simpson, M.Sc. | &nbsp;&nbsp;191284 | &nbsp;&nbsp;108590 | &nbsp;&nbsp;604019 |
| &nbsp;&nbsp;Javier Szwarcberg, M.D., MPH | &nbsp;&nbsp;293098 | &nbsp;&nbsp;6776 | &nbsp;&nbsp;604019 |

---

 **Proposal 2: Ratification of Selection of Independent Registered Public Accounting Firm.**

The Company's stockholders ratified the selection by the Audit Committee of the Board of Directors of BDO USA, P.C. as the independent registered public accounting firm of the Company for the Company's fiscal year ending December 31, 2026. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;880,984 | &nbsp;&nbsp;16,851 | &nbsp;&nbsp;6,058 | &nbsp;&nbsp;— |

---

 **Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers.**

The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on April 9, 2026. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;187,027 | &nbsp;&nbsp;111,274 | &nbsp;&nbsp;1,573 | &nbsp;&nbsp;604,019 |

---

 **Proposal 4: Advisory Vote on the Frequency of Future Advisory Votes on Executive Compensation.**

The Company's stockholders indicated, on an advisory basis, their preference for the Company to hold a stockholder advisory vote on the compensation of the Company's named executive officers every year. The voting results were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**One Year** | &nbsp;&nbsp;**Two Years** | &nbsp;&nbsp;**Three Years** | &nbsp;&nbsp;**Abstentions** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;297,804 | &nbsp;&nbsp;1,049 | &nbsp;&nbsp;804 | &nbsp;&nbsp;217 | &nbsp;&nbsp;604,019 |

---

In light of the foregoing voting results, and consistent with the recommendation of the Board of Directors, the Company has determined that it will include a non-binding stockholder advisory vote on the compensation of the Company's named executive officers in its proxy materials every year until the next required vote on the frequency of such advisory votes, which is required to occur no later than the Company's 2032 Annual Meeting of Stockholders.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Exhibit Description** |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Spruce Biosciences, Inc.** | **Spruce Biosciences, Inc.** |
| Date: May 26, 2026 | By: | &nbsp;&nbsp;&nbsp; /s/ Samir Gharib |
|  |  | Samir Gharib |
|  |  | President and Chief Financial Officer |

---

------